+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Constitutively activating mutations in the catalytic domain of c-kit receptor tyrosine kinase mediates oncogenic signaling by receptor self-association not at the extracellular domain



Constitutively activating mutations in the catalytic domain of c-kit receptor tyrosine kinase mediates oncogenic signaling by receptor self-association not at the extracellular domain



Blood 92(10 Suppl. 1 Part 1-2): 207A




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 030689776

Download citation: RISBibTeXText


Related references

Constitutively activating mutations in the juxtamembrane and kinase domains of c-kit receptor tyrosine kinase lead to receptor self-association in the cytoplasmic domain. Blood 94(10 Suppl. 1 Part 1): 46a, 1999

Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proceedings of the National Academy of Sciences of the United States of America 109(36): 14476-14481, 2012

A chimeric receptor composed of the extracellular domain of cd2 and the tyrosine kinase domain of the csf 1 receptor fms enables nih 3t3 cells to respond mitogenically to cd2 antibodies. Journal of Cellular Biochemistry Suppl. (14 Part E): 167, 1990

Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the Ron receptor. Oncogene 17(6): 741-749, 1998

Effect of transmembrane and kinase domain mutations on fibroblast growth factor receptor 3 chimera signaling in PC12 cells. A model for the control of receptor tyrosine kinase activation. Journal of Biological Chemistry 273(52): 35250-9, 1998

Preferential inhibition of constitutively activating juxtamembrane mutant rather than kinase domain mutant and wild-type c-kit receptor tyrosine kinase by tyrophostine. Blood 96(11 Part 1): 99a, 2000

Dominant negative mutations of the guanylyl cyclase-A receptor. Extracellular domain deletion and catalytic domain point mutations. Journal of Biological Chemistry 270(1): 425-430, 1995

Thrombin receptor activating mutations. Alteration of an extracellular agonist recognition domain causes constitutive signaling. Journal of Biological Chemistry 271(2): 702-706, 1996

The N-terminal extracellular domain 23-60 of the calcitonin receptor-like receptor in chimeras with the parathyroid hormone receptor mediates association with receptor activity-modifying protein 1. Biochemistry 44(15): 5749-5754, 2005

Activating mutations in the extracellular domain of the fibroblast growth factor receptor 2 function by disruption of the disulfide bond in the third immunoglobulin domain. Proceedings of the National Academy of Sciences of the United States of America 95(8): 4567-4572, 1998

Activating mutations in the extracellular domain of the fibroblast growth factor receptor 2 function by disruption of the disulfide bond in the third immunoglobulin-like domain. Proceedings of the National Academy of Sciences of the United States of America 95(8): 67-72, 1998

Lack of oncogenic mutations in the c-Met catalytic tyrosine kinase domain in acral lentiginous melanoma. International Journal of Dermatology 47(12): 1327-1329, 2008

The lck SH2 domain is required for signal transduction through the T cell antigen receptor and mediates association of lck with the ZAP-70 protein tyrosine kinase. FASEB Journal 9(3): A197, 1995

Substitution of glutamic acid for alanine-1135 in the putative catalytic loop of the tyrosine kinase domain of the human insulin receptor: A mutation that impairs proteolytic processing into subunits and inhibits receptor tyrosine kinase activity. Journal of Biological Chemistry 268(11): 8060-8069, 1993

Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clinical Cancer Research 11(16): 5878-5885, 2005